Page 1,101«..1020..1,1001,1011,1021,103..1,1101,120..»

Testosterone Therapy Treatment Types, Uses & Risks

Posted: March 12, 2020 at 3:50 am

Testosterone therapy is intended to treat male hypogonadism (low testosterone or Low T), a condition in which the body fails to make enough hormones because of a problem with the testicles, pituitary gland or brain. A number of prescription testosterone products are available to treat hypogonadism.Testosterone productscome in different forms, including gels, injectable solutions, patches, pills and pellets implanted under the skin.

Once a patient starts testosterone therapy, the patient usually undergoes lifelong treatment. Doctors will monitor the patients hormone levels every six months to a year. Depending on the patient, the checkups may be more frequent.

Fast Facts: Use of Testosterone Therapy Over the Years

Testosterone can be administered in skin patch, skin gel, pill or cream form or as an injection, a solution applied to the armpit or a patch or a buccal system applied to the upper gum or inner cheek.

While many testosterone products areavailable only with a prescription, some drug stores and health food stores sell them over the counter. A few of these products also claim to be all-natural.

Testosterone gel is a prescription medication applied directly to a mans skin on the shoulders and upper arms and/or abdomen, depending on the brand. Testosterone gel can inadvertently transfer from your body to others and can lead to serious health reactions. To avoid such contact, apply testosterone gel to clean, dry, intact skin that will be covered by clothing. Wash your hands right away with soap and water after applying. Once the gel has dried, cover the area with clothing and keep it covered until you have washed the area well or have showered.

First approved in 1979, Depo-testosterone is one of the older drugs of its kind on the market. Its a liquid and is designed for injection deep into the gluteal muscle. The active ingredient, testosterone cypionate, is a white or creamy white powder mixed with other ingredients to make a solution. The drug is available in two strengths, 100 mg and 200 mg.

Testosterone transdermal patches, including Androderm, come as patches to apply to the skin. Patches work best when applied around the same time each night and are left in place for 24 hours. Testosterone patches are meant to be worn at all times until replaced with new patches. Androderm patches should be changed every 24 hours. The old patch should be removed before applying the new one. You should apply the patches to different spots each night and wait at least seven days before re-using a spot.

The testosterone capsules Methyltestosterone and Android have been discontinued but have been used in men and boys to treat conditions caused by lack of hormone, such as delayed puberty, and in women to treat breast cancer that has spread to other parts of the body. Methyltestosterone is a man-made form of testosterone. It can affect bone growth in boys who are treated for delayed puberty.

Manufacturers of testosterone boosters like Testofen have touted their products as means to increase muscle mass, strength and sex drive in men. Among the most popular testosterone boosters are products that contain some combination of tribulus terrestris, DHEA, zinc and d-aspartic acid. These ingredients have been associated witha number of side effects, including aggressiveness, breast enlargement, cholesterol changes, prostate problems and an increased risk of cardiovascular disease.

Makers of testosterone products use two types of hormones:

Bioidentical HormonesAndroGel and a number of other products contain bioidentical hormones. Scientists create bioidentical hormones in a lab to chemically match the hormone naturally made by the body. In theory, this results in fewer side effects.

Synthetic HormonesSynthetic hormones are altered from the original chemical makeup, so they do not match those made by the body. These types of drugs typically have more side effects.

Unusually high or low levels of testosterone can significantly affect a mans physical and mental health. Men typically use testosterone drugs to address a medical issue like Low T or erectile dysfunction or to enhance their physical performance

Testosterone levels in men start to spike during puberty and drop on average by 1 percent every year after age 30. Lack of this key sex hormone in older men can cause health issues, including osteoporosis, loss of muscle mass and strength (sarcopenia), and psychological symptoms. Doctors prescribe testosterone drugs to treat these symptoms.

While declining testosterone levels tend to be part of normal aging in men, others experience the dip because of disorders of the testicles, pituitary gland and brain that cause hypogonadism. Other factors such as injury to the testicles, cancer treatments, chronic diseases and stress can also contribute to low testosterone production.

TheFDAapproved testosterone as replacement therapy only for men who have low testosterone levels due to disorders that cause hypogonadism. However, the agency has said testosterone is being widely used to try to relieve symptoms in men who have low testosterone for no apparent reason other than aging a use for which the benefits and safety have not been established.

Doctors analyze testosterone levels in two categories: total testosterone and free testosterone. Most testosterone is attached to a protein called sex hormone-binding globulin (SHGB). A small amount of testosterone is free, and a small amount regularly attaches and detaches itself from a protein called albumin. Any testosterone that is not attached to SHGB is considered free testosterone.

Some men turn to testosterone to increase sex drive and treat erectile dysfunction (ED), which is the inability to get and keep erections. In fact, according to an article published by Harvard Health Publications, some doctors used it to treat ED beforePfizerreleased Viagra in 1998.

Its well established that testosterone by itself, for men with sexual dysfunction that includes erectile dysfunction, can improve erections in the majority of men who take it.

However, only about 5 percent of men experience ED solely from low testosterone. Low testosterone levels can be a contributing factor to ED but are more likely to reduce sexual desire than cause ED. Many doctors wont consider prescribing testosterone to a patient unless he presents certain other symptoms, too.

Dr. Abraham Morgentaler is an advocate of using testosterone for treating men with sexual dysfunction, including ED.

Morgentaler does admit that some men may require testosterone andViagra, however, in order to have adequate erections.

Because testosterone allows men to increase muscle mass and performance, athletes and body builders use testosterone-boosting supplements and drugs to increase strength and improve recovery time. The practice of using these drugs is called doping. Athletes use both synthetic and bioidentical supplements. Body builders in particular are known for their use of synthetic hormones to rapidly increase muscle mass.

Testosterone can help increase muscle mass in a much faster fashion. Athletes who use anabolic steroids may find that theyre able to increase their endurance and their strength by doing the same amount of training as they would otherwise, Dr. Anthony Yin, an endocrinologist at California Pacific Medical Center in San Francisco, told SF Gate.

However, using performance-enhancing drugs, testosterone included, is illegal in most sports. While the drug is helpful to men who are clinically diagnosed with Low T, men who abuse these drugs solely to boost performance face a number of possible side effects.

As use of testosterone therapy has increased so has the amount of concern surrounding these products.

Some doctors say that in reality, few men are actually diagnosed with clinical hypogonadism, and that many symptoms are just a normal part of aging. A study published in the Journal of Clinical Endocrinology & Metabolism shows record numbers of men in the U.S. are turning to testosterone therapy simply to increase their sex drive and energy levels.

Critics say that Low T is a conditionmarketed by drug companiesto increase profits. Doctors are concerned that the long-term effects have not yet been properly studied and feel there should be more agreement about what constitutes a normal testosterone level. Because testosterone therapies are not proven treatments, they caution that risks may outweigh benefits forhealthy men.

Dr. Lisa Schwartz, a professor at the Dartmouth Institute for Health Policy and Clinical Practice, wrote a paper on drug companies marketing these hormone therapies.

Were giving people hormones that we dont know they need for a disease that we dont know they have, and we dont know if itll help them or harm them.

Over the years, men havesued the makers of testosterone productsafter using the therapies and suffering from heart attacks, strokes and blood clots. Meanwhile, researchers have conducted studies to better understand the effects of testosterone therapy.

Researchers for a year studied the effect of testosterone treatment on cognition, bone health, anemia and cardiovascular health in 788 men aged 65 or older who had low testosterone levels that couldnt be explained by anything other than age.

According to the findings, reported in February 2017 in JAMA and JAMA Internal Medicine, testosterone treatment did not have an effect on memory or cognitive abilities, though it appeared to increase hemoglobin levelsin men with anemia and improve bone density. In addition, a clinical trial found one year of testosterone treatment in men aged 65 or older with Low T was associated with a significant increase in coronary artery plaque, a risk factor for heart disease.

Studies have linked testosterone products to serious side effects, prompting the FDA to take action in recent years towarn the publicof the potential dangers of these products.

Testosterone therapy is associated with an increased risk for these health problems:

Testosterone therapy for men can be dangerous to women and children if they come in contact with the drug by touching the patients skin. This usually occurs when men use testosterone gel and the application site is exposed. Anyone who comes in contact with the application site is at risk of developing side effects.

Women can experience acne or hair growth, and if they are pregnant, the unborn baby may be harmed.

In 2009, the FDA issued a warning about adverse effects in children exposed to testosterone gels through contact with application sites. Symptoms included abnormally large genitalia (penis and clitoris), advanced bone age, early puberty and aggressive behavior. Young boys may even develop enlarged breasts. A doctor should be contacted right away if these symptoms occur.

Pets exposed to testosterone can become violent and aggressive and develop enlarged genitals.

Read more here:
Testosterone Therapy Treatment Types, Uses & Risks

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Therapy Treatment Types, Uses & Risks

Testosterone Replacement Therapy for Women: Pros and Cons

Posted: March 12, 2020 at 3:50 am

There are many positive benefits of testosterone therapy. While testosterone is the male hormone, and testosterone replacement therapy is most often used to treat men with low testosterone, you may be surprised to learn that women can benefit from testosterone therapy as well.

Even though testosterone is an androgen, or male hormone, womens bodies do make and need testosterone, albeit, not as much as men, and for different things than men do. Unlike being necessary in vast amounts to provide for the development of maleness in men, in women, testosterone is necessary for:

When a women is experiencing low testosterone, all of the above can be negatively affected.

As in men, a womans testosterone level can fluctuate throughout the day, and can be impacted by many things from diet to her menstrual cycle. However, as in their male counterparts, the most significant drain on testosterone levels in women, occurs from the impact of ageing.

When you think about hormone replacement therapy (HRT) for women, the first thought that usually comes to mind is the typical estrogen therapy that is used to treat menopausal symptoms. However, when a woman is going through menopause, along with estrogen depletion, she is also losing her ability to produce adequate amounts of testosterone. A woman with low testosterone, will have trouble producing new blood cells, maintaining her libido or sex drive, and will find it harder to build muscle and burn fat.

When this is the case she will show the signs of low testosterone. The signs and symptoms of low testosterone in woman include:

Current research indicates that women who are on estrogen replacement for menopausal symptoms, can also benefit when testosterone therapy is added as an adjunct to estrogen replacement in these women. Testosterone, when used in this way, seems to specifically help with the sexual wellness issues typical of post-menopausal women. According to Dr. Alan Malabanan, assistant professor of medicine at Harvard Medical School, Studies of postmenopausal women have found that taking testosterone (often in addition to the hormone therapy women are already taking to treat menopause symptoms) increases sexual desire and pleasure compared with a placebo (inactive treatment).

In addition to helping women with the sexual health issues that often occur as they age, and testosterone levels drop, testosterone therapy has also been shown to help women in other matters of overall health and wellness. One of the most widely respected studies showing testosterones importance in maintaining a womans general health as well as sexual satisfaction was published in 2000 in the New England Journal of Medicine. Using traditionally accepted randomized, double-blind, placebo-controlled methodology, this study concluded that, transdermal testosterone improves sexual function and psychological well-being. Transdermal testosterone is a form of testosterone replacement therapy that is given using transdermal (skin) patches.

In addition to increasing the libido, and increasing health and vitality overall, testosterone therapy in women can also:

Testosterone is vital to the strength, vitality, and wellbeing of both men and women. However, in women, testosterone therapy must be given with particular care. In women, testosterone therapy is rarely given alone, but is prescribed as part of an overall program of Hormone Replacement Therapy (HRT) designed to bring all of her hormones back into proper balance.

Therefore it is imperative that any women who thinks that she may benefit from testosterone therapy, seek her treatment from a doctor, or HRT clinic that is skilled and experienced. This way, she can be sure that she will be getting the very best testosterone therapy tailored to her unique needs, body, and lifestyle.

Excerpt from:
Testosterone Replacement Therapy for Women: Pros and Cons

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy for Women: Pros and Cons

Testosterone Replacement Therapy Market Organization Sizes Analysis 2019-2025 – Packaging News 24

Posted: March 12, 2020 at 3:50 am

Testosterone Replacement Therapy Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Testosterone Replacement Therapy market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Testosterone Replacement Therapy is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Testosterone Replacement Therapy market was valued at USD _ million/billion.

This research report based on Testosterone Replacement Therapy market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Testosterone Replacement Therapy market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Testosterone Replacement Therapy industry.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2611333&source=atm

Testosterone Replacement Therapy Market Overview:

The Research projects that the Testosterone Replacement Therapy market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Testosterone Replacement Therapy Market:

The major players profiled in this report include:AbbVieAllerganBayer Eli Lilly and CompanyKyowa Kirin InternationalNovartis Pfizer

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Testosterone Replacement Therapy for each application, including-Medical

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2611333&source=atm

Some important highlights from the report include:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2611333&licType=S&source=atm

The Questions Answered by Testosterone Replacement Therapy Market Report:

And Many More.

Read more here:
Testosterone Replacement Therapy Market Organization Sizes Analysis 2019-2025 - Packaging News 24

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Market Organization Sizes Analysis 2019-2025 – Packaging News 24

Testosterone Replacement Therapy Market Current Status, Historical Analysis and Forecast 2020 to 2025 – Fashion Trends News

Posted: March 12, 2020 at 3:50 am

The Global Testosterone Replacement Therapy Market 2020 Industry Trends and Forecasts to 2025 is a professional and in-depth study on the current state of the Testosterone Replacement Therapy market. Annual estimates and forecasts are provided for the period 2020 through 2025. Also, a six-year historic analysis is presented for these Testosterone Replacement Therapy businesses. The global market for Testosterone Replacement Therapy is presumed to reach about xx by 2025 from xx in 2020, joining a Compound Annual Growth Rate (CAGR) of xx % during the analysis years, 2020-2025.

The report presents a primary overview of the Testosterone Replacement Therapy industry including definitions, classifications, applications, and business chain structure. And developing strategies and programs are addressed as well as manufacturing methods and cost formations.

Click here!!!! To Download Free PDF Illustrative Brochure (Contains- Keyplayers, Growth Value, Segments, etc) @ https://www.eonmarketresearch.com/sample/58743

This report analyzing Testosterone Replacement Therapy centers on Top Companies in the global market, with capacity, production, value, income, and market share for each manufacturer, including

AbbVieAllerganBayerEli Lilly and CompanyKyowa Kirin InternationalNovartisPfizer

Global Testosterone Replacement Therapy Market 2020: Product Type Segment Analysis

General Type

Global Testosterone Replacement Therapy Market 2020: Applications Segment Analysis

Medical

Then, the Testosterone Replacement Therapy market study report concentrates on global higher leading business players with knowledge such as company profiles, product picture and specifications, sales, market share, and association information. Whats more, the Testosterone Replacement Therapy industry development trends and marketing channels are examined.

Market Segment by Regions, this report splits Global into rare key Countries, with production, expenditure, revenue, market share, and growth rate of Testosterone Replacement Therapy in these countries, from 2020 to 2025 (forecast), similar North America, Europe, Japan, Southeast Asia, India, and China.

In a word, the Testosterone Replacement Therapy market report gives important statistics on the state of the Testosterone Replacement Therapy industry and is a helpful source of guidance and direction for companies and individuals interested in the Testosterone Replacement Therapy market.

Place An Inquiry Before Buying @ https://www.eonmarketresearch.com/enquiry/58743

Table of Contents

1. Testosterone Replacement Therapy Market Overview, Scope, Segment- by Types, Applications and Regions, World Market Size and of Testosterone Replacement Therapy and Country wise Status and Prospect (2015-2025).

2. Global Testosterone Replacement Therapy Market Competition by Manufacturers- Global Testosterone Replacement Therapy Production, Revenue and Share by Manufacturers (2018 and 2020), Testosterone Replacement Therapy Industry Competitive Situation and Trends.

3. Global Testosterone Replacement Therapy Production, Revenue (Value) by Regions (North America, EU, Japan, India, and China) (2015-2020).

4. Global Testosterone Replacement Therapy Supply (Production), Consumption, Export, Import by Nations (2015-2020).

5. Global Testosterone Replacement Therapy Production, Revenue (Value), Price Trend by Types (2015-2020).

6. Global Testosterone Replacement Therapy Market Analysis by Applications and Study of Market Drivers and Opportunities.

7. Global Testosterone Replacement Therapy Manufacturers Profiles/Analysis- Company Basic Information, Manufacturing Base and Sales Area, Testosterone Replacement Therapy Product Types, Application and Specification, Production, Revenue, Price and Gross Margin (2018 and 2020) and Business Overview.

8. Analysis of Testosterone Replacement Therapy Industrial Chain Analysis, Sourcing Strategy and Downstream Buyers.

10. In this report study Testosterone Replacement Therapy Marketing Channel, Positioning and Strategy Analysis and List of Testosterone Replacement Therapy Distributors/Traders.

11. Global Testosterone Replacement Therapy Market Production and Price Forecast by Countries, Type, and Application (2020-2025).

12. Research Findings and Conclusion.

About Us:

Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: sales@eonmarketresearch.com

View post:
Testosterone Replacement Therapy Market Current Status, Historical Analysis and Forecast 2020 to 2025 - Fashion Trends News

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Market Current Status, Historical Analysis and Forecast 2020 to 2025 – Fashion Trends News

Longevity And Anti-Senescence Therapy Market Overview, Consumption, Supply, Demand & Insights – Kentucky Journal 24

Posted: March 12, 2020 at 3:49 am

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Get Sample Copy Of The Report@https://www.trendsmarketresearch.com/report/sample/11698

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Request For Report Discount@https://www.trendsmarketresearch.com/report/discount/11698

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

Report Analysis@https://www.trendsmarketresearch.com/report/analysis/BCC/global-longevity-and-anti-senescence-therapy-market

See the rest here:
Longevity And Anti-Senescence Therapy Market Overview, Consumption, Supply, Demand & Insights - Kentucky Journal 24

Posted in Kentucky Stem Cells | Comments Off on Longevity And Anti-Senescence Therapy Market Overview, Consumption, Supply, Demand & Insights – Kentucky Journal 24

Diabetes – Symptoms, Diagnosis, Treatments & Complications

Posted: March 12, 2020 at 3:48 am

When doctors first discovered diabetes in the early 1900s, there were few options for treatment. It wasnt until the 1990s that people with Type 2 diabetes had oral medications like metformin still a mainstay of treatment for many people with diabetes.

Insulin, a necessary treatment for patients with Type 1 diabetes, remains one of the biggest medical discoveries to this day. Prior to its unearthing in the early 1920s, led primarily by Dr. Frederick Banting of Toronto, Canada, diabetes was a dreaded disease that led to certain death. A strict diet to minimize sugar intake, which sometimes caused death by starvation, was the most effective treatment, possibly buying patients a few more years to live.

Banting and one of his colleagues were awarded the Nobel Peace Prize for their discovery in 1923. That same year, drug manufacturer Eli Lilly started large-scale production of insulin, producing enough to supply all of North America.

Now, in addition to injected insulin, there are a number of oral medication classes to choose from, all with their own benefits and risks. Butdiet and exerciseare still an important part of both Type 1 and Type 2 diabetes treatment. Now, even special types of surgery can help people with both types of diabetes manage their blood sugar.

A doctor may recommend one type of treatment or a combination of the three.

When changes in diet and increased physical activity are not enough to control blood glucose levels, doctors will prescribe medications. These same medications, aside from insulin, are not used, however, to treat patients with Type 1 diabetes. Insulin is the only medication prescribed to treat Type 1 diabetes, and Type 1 patients are required to take the hormone replacement daily. However, there are several different types, or classes, of medications available to treat Type 2 diabetes. Each controls blood sugar in different ways. Some people may take more than one medication to more effectively control sugar levels.

Type 2 Diabetes Groups

There are many medications to treat Type 2 diabetes, and typically they are organized into groups that represent the condition that they target. These drugs are then organized into classes by mechanism of action.

A new class of diabetes medications calledsodium-glucose co-transporter 2 (SGLT2) inhibitorsrelease excess glucose in the body through urination. The FDA approved Invokana (canagliflozin), the first drug in the class, in 2013. Several others followed. But the agency has also released a number of warnings for serious side effects linked to these medications.

Popular Drugs in This Class Include:

Side Effects of SGLT2 Inhibitors May Include:

The FDA warned UTIs caused by SGLT2s can lead to other serious infections. The first is urosepsis, a serious systemic blood infection that can be fatal. The second is pyelonephritis, a serious kidney infection. Pyelonephritis may also lead to a blood infection. Both types of infection require hospitalization and antibiotics.

Additional FDA safety communications warned aboutkidney injuryand diabetic ketoacidosis, a condition that occurs when too many toxins build up in the blood. New studies also show these drugs may also cause acute pancreatitis, a condition caused by the swelling and inflammation of the pancreas the organ that produces insulin.

Biguanides are a class of drugs that work by making the body more sensitive to insulin. They also stop the liver from making glucose and releasing it into the blood. They may also make fat and muscle cells more insulin sensitive.

Currently, there is only one drug in this class available on the market: Glucophage (metformin). This is one of the most widely used Type 2 diabetes medications in the world. Since it has been around since the 1920s, its side effects are very well known. It became available in the U.S. in the 1990s. Many doctors are very comfortable prescribing it as a frontline medication or incombination with other medications.

In fact, most combination oral medications contain metformin. Newer drugs also test their effectiveness against metformin in clinical trials.

Metformin's Side Effects May Include:

TZDs work by decreasing blood glucose levels by making muscle, fat and liver cells more sensitive to insulin. The FDA approved many of these drugs in the 1990s. The two most popular drugs in this class areActosandAvandia. But these drugs were linked to serious side effects including bladder cancer and heart failure.

It has been one of the most popular drugs in the United States for treating Type 2 diabetes since 2007. It has only been on the market since 1999. The drug recently came under fire for causing an increased risk of congestive heart failure and its link to bladder cancer. The drugs maker, Takeda, paid $2.37 billion to settle thousands of lawsuits by people who claimed Actos caused their bladder cancer.

This drug comes from the same controversial class of drugs as Actos, and works in a similar way. Studies link it to an increased risk of heart failure. A number of countries in Europe stopped selling the drug and banned it. Although not banned in the United States, it can only be prescribed by a small group of doctors.

TDS side effects may include:

These drugs stimulate the pancreas to produce more insulin. There are several well-known Type 2 diabetes drugs that use sulfonylureas as their base. These include Glucotrol (glipizide), Diabeta (glyburide) and several others. TheFDA approvedthe first of these drugs in the 1980s.

These work to decrease blood glucose levels by stimulating insulin release by the beta cells in the pancreas. Pancreatic beta cells are the cells primarily responsible for releasing insulin.

Side effects of sulfonylureas include:

One of the issues with Type 2 diabetes is glucose entering the bloodstream faster than the body can process it. Slowing the digestive process of starches and sugars slows down the rate that glucose enters the bloodstream.

These drugs slow the digestion of sugar. Because these medications affect the digestive system, side effects of nausea and flatulence are common. Alpha-glucosidase inhibitors are the least effective medications for lowering blood sugar and are rarely used in the United States. Precose (acarbose) and Glyset (miglitol) belong to this class. Amylin analogues also have a modest effect on blood sugar, and are injected with a dosing pen. The only product available is called pramlintide.

These drugs keep the hormone incretin from being broken down, stimulating insulin production and slowing digestion. Popular brand names are Januvia, Onglyza and Tradjenta. Generic names are sitagliptin, saxagliptin and linagliptin. Side effects include: joint pain, pancreatitis, sore throat, swelling of hands or feet, nausea, hypoglycemia and diarrhea.

Everyone with Type 1 diabetes must take insulin every day. However, patients diagnosed with Type 2 diabetes sometimes need to take insulin as well, when oral medications taken along with diet and exercise, are no longer enough to control the disease on their own. Some reasons why people with Type 2 may need to start taking insulin, even if just temporarily, often involve other health conditions, injury, medication use or any other physiological change that can cause an individuals body to become unable to produce enough insulin.

These reasons might include:

Insulin is injected under the skin (called a subcutaneous injection) using a syringe, insulin pen or insulin pump. The abdomen is the preferred injection site due to a more consistent absorption of insulin occurring in this region. However, the location for injections should be rotated regularly to avoid a condition called lipodystrophy, or erosion of the fat beneath the skin. Other popular injection sites include the thigh and the arm.

Insulin is not available to be taken in an oral form because stomach acid destroys the hormone. However, there is an inhaled version of the drug sold under the brand name Afrezza. This is a powder that is breathed in just before a meal (rapid-acting).

Doses of insulin vary by patient. How much insulin a patient requires daily depends on several factors, including:

In patients with Type 2 diabetes, insulin may be stopped if temporary situations necessitating its use are resolved, or sometimes with weight loss, exercise or other lifestyle changes. Patients with Type 1 diabetes will never be able to stop taking insulin, although doses may be adjusted.

There are four different types of insulin that work differently for patients with diabetes rapid-acting, short-acting, intermediate-acting and long-acting. Rapid-acting and short-acting insulins are often used in combination with longer-acting insulins. Both rapid- and short-acting insulins are taken shortly before meals (usually about 30 minutes prior) to cover the rise in blood glucose levels that results from eating.

Intermediate- and long-acting insulins cover any elevations in blood glucose levels after the shorter acting insulins stop working. Intermediate-acting insulin is usually taken twice a day, while long-acting insulin is taken once or twice a day.

The following chart breaks down the different types of insulin and how they work.

Insulin is generally considered safe to take. It is even the preferred drug, over oral drugs, to control blood glucose levels during pregnancy and when breastfeeding. However, insulin is not without side effects. Hypoglycemia (low blood sugar) is the most common side effect experienced in patients taking insulin.

Other Insulin Side Effects Might Include:

Healthy eating helps keep blood sugar down and is a critical part of managing both Type 1 and Type 2 diabetes, according to the National Institutes of Health. In fact, healthy eating is a part of a diabetic patients treatment plan, along with insulin for primarily Type 1 patients or another prescribed medication for patients with Type 2. Type 1 patients are also required to count carbohydrates and frequently monitor their blood sugar levels. Type 2 patients should be mindful of their blood sugar levels before and after eating as well.

The NIH recommends talking to a registered dietitian or nutritionist to develop an eating plan that works around eachindividuals lifestyle, weight, medicines and other health problems. The National Institute of Diabetes and Digestive and Kidney Diseases has tips for healthy eating.

These include:

Exercise is also beneficial for controlling blood glucose. Both Type 1 and Type 2 patients can benefit from exercising regularly and maintaining a healthy weight. A personal trainer or a diabetes expert can help you set meaningful goals. An exercise plan does not have to be strenuous to impart benefits.

In fact, new research in the journal Diabetologia shows that short 10-minute walks after meals can help lower blood sugar. Researchers at the University of Otago in New Zealand found these short walks after meals helped control blood glucose better than a single 30-minute walk by 12 percent.

Other 2016 research in Diabetologia by Dr. Bernard Duvivier of Maastricht University in the Netherlands found simply sitting less and by standing more and doing light walking may control blood sugar better than higher intensity exercise.

Exercise can cause blood sugar levels to drop, especially in diabetic patients taking insulin. Patients with diabetes should regularly monitor their blood sugar levels before, during and after physical activity to make sure they dont get too low.

Additionally, after administering insulin, strenuous activity can potentially speed up the bodys absorption of the hormone. Patients who plan to exercise following an insulin injection, should not inject themselves in an area that is most likely to be affected by the activity. For example, patients who plan to go running soon after the injection of insulin, should not inject the hormone into their thigh.

Bariatric surgery is growing in popularity as a treatment for Type 2 diabetes. There are a few methods of performing the surgery, but they all involve shrinking the size of the stomach or rerouting the path of food.

As with any surgery, there are risks, including:

The most familiar type of surgery is gastric bypass. It creates a small pouch at the top of the stomach about the size of a walnut. The surgeon then reconnects the small intestine to this new walnut-sized stomach.

One study published in 2011 in Diabetes Care showed the surgery is highly effective in very obese patients with Type 2 diabetes. A review of clinical literature showed diabetes death rates lowered by up to 90 percent after gastric-bypass surgery.

Overweight patients with poorly controlled Type 1 diabetes may make good candidates for surgery as well. Such operations may give Type 1 patients greater control over the disease not a cure.

They may experience a possible reduction in daily insulin doses, according to a review of cases from the Cleveland Clinic in Ohio.

One study conducted at Cleveland Clinic showed that 9 out of 10 morbidly obese patients with Type 1 who underwent a laparoscopic procedure, such as a gastric bypass, lost more than 60 percent of their body weight in more than three years time. These patients also saw improvements in all cardiovascular risk factors, such as hypertension (high blood pressure) and triglyceride levels (the most common type of fat found in the blood).

Other Pages Related to Diabetes

See the rest here:
Diabetes - Symptoms, Diagnosis, Treatments & Complications

Posted in Diabetes | Comments Off on Diabetes – Symptoms, Diagnosis, Treatments & Complications

Type 2 diabetes – Genetics Home Reference – NIH

Posted: March 12, 2020 at 3:48 am

Andersen MK, Pedersen CE, Moltke I, Hansen T, Albrechtsen A, Grarup N. Genetics of Type 2 Diabetes: the Power of Isolated Populations. Curr Diab Rep. 2016 Jul;16(7):65. doi: 10.1007/s11892-016-0757-z. Review.

Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017 Jun 3;389(10085):2239-2251. doi: 10.1016/S0140-6736(17)30058-2. Epub 2017 Feb 10. Review.

DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium; Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; Mexican American Type 2 Diabetes (MAT2D) Consortium; Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples (T2D-GENES) Consortium, Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, Horikoshi M, Johnson AD, Ng MC, Prokopenko I, Saleheen D, Wang X, Zeggini E, Abecasis GR, Adair LS, Almgren P, Atalay M, Aung T, Baldassarre D, Balkau B, Bao Y, Barnett AH, Barroso I, Basit A, Been LF, Beilby J, Bell GI, Benediktsson R, Bergman RN, Boehm BO, Boerwinkle E, Bonnycastle LL, Burtt N, Cai Q, Campbell H, Carey J, Cauchi S, Caulfield M, Chan JC, Chang LC, Chang TJ, Chang YC, Charpentier G, Chen CH, Chen H, Chen YT, Chia KS, Chidambaram M, Chines PS, Cho NH, Cho YM, Chuang LM, Collins FS, Cornelis MC, Couper DJ, Crenshaw AT, van Dam RM, Danesh J, Das D, de Faire U, Dedoussis G, Deloukas P, Dimas AS, Dina C, Doney AS, Donnelly PJ, Dorkhan M, van Duijn C, Dupuis J, Edkins S, Elliott P, Emilsson V, Erbel R, Eriksson JG, Escobedo J, Esko T, Eury E, Florez JC, Fontanillas P, Forouhi NG, Forsen T, Fox C, Fraser RM, Frayling TM, Froguel P, Frossard P, Gao Y, Gertow K, Gieger C, Gigante B, Grallert H, Grant GB, Grrop LC, Groves CJ, Grundberg E, Guiducci C, Hamsten A, Han BG, Hara K, Hassanali N, Hattersley AT, Hayward C, Hedman AK, Herder C, Hofman A, Holmen OL, Hovingh K, Hreidarsson AB, Hu C, Hu FB, Hui J, Humphries SE, Hunt SE, Hunter DJ, Hveem K, Hydrie ZI, Ikegami H, Illig T, Ingelsson E, Islam M, Isomaa B, Jackson AU, Jafar T, James A, Jia W, Jckel KH, Jonsson A, Jowett JB, Kadowaki T, Kang HM, Kanoni S, Kao WH, Kathiresan S, Kato N, Katulanda P, Keinanen-Kiukaanniemi KM, Kelly AM, Khan H, Khaw KT, Khor CC, Kim HL, Kim S, Kim YJ, Kinnunen L, Klopp N, Kong A, Korpi-Hyvlti E, Kowlessur S, Kraft P, Kravic J, Kristensen MM, Krithika S, Kumar A, Kumate J, Kuusisto J, Kwak SH, Laakso M, Lagou V, Lakka TA, Langenberg C, Langford C, Lawrence R, Leander K, Lee JM, Lee NR, Li M, Li X, Li Y, Liang J, Liju S, Lim WY, Lind L, Lindgren CM, Lindholm E, Liu CT, Liu JJ, Lobbens S, Long J, Loos RJ, Lu W, Luan J, Lyssenko V, Ma RC, Maeda S, Mgi R, Mnnisto S, Matthews DR, Meigs JB, Melander O, Metspalu A, Meyer J, Mirza G, Mihailov E, Moebus S, Mohan V, Mohlke KL, Morris AD, Mhleisen TW, Mller-Nurasyid M, Musk B, Nakamura J, Nakashima E, Navarro P, Ng PK, Nica AC, Nilsson PM, Njlstad I, Nthen MM, Ohnaka K, Ong TH, Owen KR, Palmer CN, Pankow JS, Park KS, Parkin M, Pechlivanis S, Pedersen NL, Peltonen L, Perry JR, Peters A, Pinidiyapathirage JM, Platou CG, Potter S, Price JF, Qi L, Radha V, Rallidis L, Rasheed A, Rathman W, Rauramaa R, Raychaudhuri S, Rayner NW, Rees SD, Rehnberg E, Ripatti S, Robertson N, Roden M, Rossin EJ, Rudan I, Rybin D, Saaristo TE, Salomaa V, Saltevo J, Samuel M, Sanghera DK, Saramies J, Scott J, Scott LJ, Scott RA, Segr AV, Sehmi J, Sennblad B, Shah N, Shah S, Shera AS, Shu XO, Shuldiner AR, Sigursson G, Sijbrands E, Silveira A, Sim X, Sivapalaratnam S, Small KS, So WY, Stankov A, Stefansson K, Steinbach G, Steinthorsdottir V, Stirrups K, Strawbridge RJ, Stringham HM, Sun Q, Suo C, Syvnen AC, Takayanagi R, Takeuchi F, Tay WT, Teslovich TM, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tikkanen E, Trakalo J, Tremoli E, Trip MD, Tsai FJ, Tuomi T, Tuomilehto J, Uitterlinden AG, Valladares-Salgado A, Vedantam S, Veglia F, Voight BF, Wang C, Wareham NJ, Wennauer R, Wickremasinghe AR, Wilsgaard T, Wilson JF, Wiltshire S, Winckler W, Wong TY, Wood AR, Wu JY, Wu Y, Yamamoto K, Yamauchi T, Yang M, Yengo L, Yokota M, Young R, Zabaneh D, Zhang F, Zhang R, Zheng W, Zimmet PZ, Altshuler D, Bowden DW, Cho YS, Cox NJ, Cruz M, Hanis CL, Kooner J, Lee JY, Seielstad M, Teo YY, Boehnke M, Parra EJ, Chambers JC, Tai ES, McCarthy MI, Morris AP. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014 Mar;46(3):234-44. doi: 10.1038/ng.2897. Epub 2014 Feb 9.

Flannick J, Florez JC. Type 2 diabetes: genetic data sharing to advance complex disease research. Nat Rev Genet. 2016 Sep;17(9):535-49. doi: 10.1038/nrg.2016.56. Epub 2016 Jul 11. Review.

Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, Ma C, Fontanillas P, Moutsianas L, McCarthy DJ, Rivas MA, Perry JRB, Sim X, Blackwell TW, Robertson NR, Rayner NW, Cingolani P, Locke AE, Tajes JF, Highland HM, Dupuis J, Chines PS, Lindgren CM, Hartl C, Jackson AU, Chen H, Huyghe JR, van de Bunt M, Pearson RD, Kumar A, Mller-Nurasyid M, Grarup N, Stringham HM, Gamazon ER, Lee J, Chen Y, Scott RA, Below JE, Chen P, Huang J, Go MJ, Stitzel ML, Pasko D, Parker SCJ, Varga TV, Green T, Beer NL, Day-Williams AG, Ferreira T, Fingerlin T, Horikoshi M, Hu C, Huh I, Ikram MK, Kim BJ, Kim Y, Kim YJ, Kwon MS, Lee J, Lee S, Lin KH, Maxwell TJ, Nagai Y, Wang X, Welch RP, Yoon J, Zhang W, Barzilai N, Voight BF, Han BG, Jenkinson CP, Kuulasmaa T, Kuusisto J, Manning A, Ng MCY, Palmer ND, Balkau B, Stankov A, Abboud HE, Boeing H, Giedraitis V, Prabhakaran D, Gottesman O, Scott J, Carey J, Kwan P, Grant G, Smith JD, Neale BM, Purcell S, Butterworth AS, Howson JMM, Lee HM, Lu Y, Kwak SH, Zhao W, Danesh J, Lam VKL, Park KS, Saleheen D, So WY, Tam CHT, Afzal U, Aguilar D, Arya R, Aung T, Chan E, Navarro C, Cheng CY, Palli D, Correa A, Curran JE, Rybin D, Farook VS, Fowler SP, Freedman BI, Griswold M, Hale DE, Hicks PJ, Khor CC, Kumar S, Lehne B, Thuillier D, Lim WY, Liu J, van der Schouw YT, Loh M, Musani SK, Puppala S, Scott WR, Yengo L, Tan ST, Taylor HA Jr, Thameem F, Wilson G Sr, Wong TY, Njlstad PR, Levy JC, Mangino M, Bonnycastle LL, Schwarzmayr T, Fadista J, Surdulescu GL, Herder C, Groves CJ, Wieland T, Bork-Jensen J, Brandslund I, Christensen C, Koistinen HA, Doney ASF, Kinnunen L, Esko T, Farmer AJ, Hakaste L, Hodgkiss D, Kravic J, Lyssenko V, Hollensted M, Jrgensen ME, Jrgensen T, Ladenvall C, Justesen JM, Krjmki A, Kriebel J, Rathmann W, Lannfelt L, Lauritzen T, Narisu N, Linneberg A, Melander O, Milani L, Neville M, Orho-Melander M, Qi L, Qi Q, Roden M, Rolandsson O, Swift A, Rosengren AH, Stirrups K, Wood AR, Mihailov E, Blancher C, Carneiro MO, Maguire J, Poplin R, Shakir K, Fennell T, DePristo M, de Angelis MH, Deloukas P, Gjesing AP, Jun G, Nilsson P, Murphy J, Onofrio R, Thorand B, Hansen T, Meisinger C, Hu FB, Isomaa B, Karpe F, Liang L, Peters A, Huth C, O'Rahilly SP, Palmer CNA, Pedersen O, Rauramaa R, Tuomilehto J, Salomaa V, Watanabe RM, Syvnen AC, Bergman RN, Bharadwaj D, Bottinger EP, Cho YS, Chandak GR, Chan JCN, Chia KS, Daly MJ, Ebrahim SB, Langenberg C, Elliott P, Jablonski KA, Lehman DM, Jia W, Ma RCW, Pollin TI, Sandhu M, Tandon N, Froguel P, Barroso I, Teo YY, Zeggini E, Loos RJF, Small KS, Ried JS, DeFronzo RA, Grallert H, Glaser B, Metspalu A, Wareham NJ, Walker M, Banks E, Gieger C, Ingelsson E, Im HK, Illig T, Franks PW, Buck G, Trakalo J, Buck D, Prokopenko I, Mgi R, Lind L, Farjoun Y, Owen KR, Gloyn AL, Strauch K, Tuomi T, Kooner JS, Lee JY, Park T, Donnelly P, Morris AD, Hattersley AT, Bowden DW, Collins FS, Atzmon G, Chambers JC, Spector TD, Laakso M, Strom TM, Bell GI, Blangero J, Duggirala R, Tai ES, McVean G, Hanis CL, Wilson JG, Seielstad M, Frayling TM, Meigs JB, Cox NJ, Sladek R, Lander ES, Gabriel S, Burtt NP, Mohlke KL, Meitinger T, Groop L, Abecasis G, Florez JC, Scott LJ, Morris AP, Kang HM, Boehnke M, Altshuler D, McCarthy MI. The genetic architecture of type 2 diabetes. Nature. 2016 Aug 4;536(7614):41-47. doi: 10.1038/nature18642. Epub 2016 Jul 11.

McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010 Dec 9;363(24):2339-50. doi: 10.1056/NEJMra0906948. Review.

Mohlke KL, Boehnke M. Recent advances in understanding the genetic architecture of type 2 diabetes. Hum Mol Genet. 2015 Oct 15;24(R1):R85-92. doi: 10.1093/hmg/ddv264. Epub 2015 Jul 9. Review.

Morris AP, Voight BF, Teslovich TM, Ferreira T, Segr AV, Steinthorsdottir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A, Prokopenko I, Kang HM, Dina C, Esko T, Fraser RM, Kanoni S, Kumar A, Lagou V, Langenberg C, Luan J, Lindgren CM, Mller-Nurasyid M, Pechlivanis S, Rayner NW, Scott LJ, Wiltshire S, Yengo L, Kinnunen L, Rossin EJ, Raychaudhuri S, Johnson AD, Dimas AS, Loos RJ, Vedantam S, Chen H, Florez JC, Fox C, Liu CT, Rybin D, Couper DJ, Kao WH, Li M, Cornelis MC, Kraft P, Sun Q, van Dam RM, Stringham HM, Chines PS, Fischer K, Fontanillas P, Holmen OL, Hunt SE, Jackson AU, Kong A, Lawrence R, Meyer J, Perry JR, Platou CG, Potter S, Rehnberg E, Robertson N, Sivapalaratnam S, Stankov A, Stirrups K, Thorleifsson G, Tikkanen E, Wood AR, Almgren P, Atalay M, Benediktsson R, Bonnycastle LL, Burtt N, Carey J, Charpentier G, Crenshaw AT, Doney AS, Dorkhan M, Edkins S, Emilsson V, Eury E, Forsen T, Gertow K, Gigante B, Grant GB, Groves CJ, Guiducci C, Herder C, Hreidarsson AB, Hui J, James A, Jonsson A, Rathmann W, Klopp N, Kravic J, Krjutkov K, Langford C, Leander K, Lindholm E, Lobbens S, Mnnist S, Mirza G, Mhleisen TW, Musk B, Parkin M, Rallidis L, Saramies J, Sennblad B, Shah S, Sigursson G, Silveira A, Steinbach G, Thorand B, Trakalo J, Veglia F, Wennauer R, Winckler W, Zabaneh D, Campbell H, van Duijn C, Uitterlinden AG, Hofman A, Sijbrands E, Abecasis GR, Owen KR, Zeggini E, Trip MD, Forouhi NG, Syvnen AC, Eriksson JG, Peltonen L, Nthen MM, Balkau B, Palmer CN, Lyssenko V, Tuomi T, Isomaa B, Hunter DJ, Qi L; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology NetworkType 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium, Shuldiner AR, Roden M, Barroso I, Wilsgaard T, Beilby J, Hovingh K, Price JF, Wilson JF, Rauramaa R, Lakka TA, Lind L, Dedoussis G, Njlstad I, Pedersen NL, Khaw KT, Wareham NJ, Keinanen-Kiukaanniemi SM, Saaristo TE, Korpi-Hyvlti E, Saltevo J, Laakso M, Kuusisto J, Metspalu A, Collins FS, Mohlke KL, Bergman RN, Tuomilehto J, Boehm BO, Gieger C, Hveem K, Cauchi S, Froguel P, Baldassarre D, Tremoli E, Humphries SE, Saleheen D, Danesh J, Ingelsson E, Ripatti S, Salomaa V, Erbel R, Jckel KH, Moebus S, Peters A, Illig T, de Faire U, Hamsten A, Morris AD, Donnelly PJ, Frayling TM, Hattersley AT, Boerwinkle E, Melander O, Kathiresan S, Nilsson PM, Deloukas P, Thorsteinsdottir U, Groop LC, Stefansson K, Hu F, Pankow JS, Dupuis J, Meigs JB, Altshuler D, Boehnke M, McCarthy MI; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012 Sep;44(9):981-90. doi: 10.1038/ng.2383. Epub 2012 Aug 12.

Pal A, McCarthy MI. The genetics of type 2 diabetes and its clinical relevance. Clin Genet. 2013 Apr;83(4):297-306. doi: 10.1111/cge.12055. Epub 2012 Dec 4. Review.

See the rest here:
Type 2 diabetes - Genetics Home Reference - NIH

Posted in Diabetes | Comments Off on Type 2 diabetes – Genetics Home Reference – NIH

Diabetes – Physiopedia

Posted: March 12, 2020 at 3:48 am

Introduction

Diabetes is a metabolic disorder in which the body is unable to appropriately regulate the level of sugar, specificallyglucose, in the blood, either by poor sensitivity to the protein insulin, or due to inadequate production of insulin by thepancreas. Type 2 diabetes accounts for 90-95% of all diabetes cases. Diabetes itself is not a high-mortality condition(1.3 million deaths globally), but it is a major risk factor for other causes of death and has a high attributable burden ofdisability. Diabetes is also a major risk factor for cardiovascular disease, kidney disease and blindness.[1]

Be sure to also read:

Diabetes Mellitus primarily affects the Islets of Langerhans of the pancreas, where glucagon (from the alpha cells) and insulin (from the beta cells)are produced. Glucagon raises the blood glucose level, while insulin lowers it.In Type 1 DM (Insulin Dependent), the loss of function of the beta cells leads to an absolute insulin deficiency. In Type 2 DM(Non-insulin Dependent), the impaired production and secretion of insulin by the beta cells is concomitant with the impaired ability of the tissues to utilize insulin (termed insulin resistance). The resulting accumulation of glucose in the blood is further elevated by the greater synthesis of glucose in the liver, which releases it to the general circulation.

Diabetes Mellitus (both Type 1 and Type 2) is now a global epidemic. Usually correlated with being overweight and obese, a sedentary lifestyle and familial history are also beingconsidered as risk factors.

According to the research entitled "Global Prevalence of Diabetes" by Sarah Wild, MB, BCHIR, PhD, and associates[2], "the total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. The prevalence of diabetes is higher in men than women, but there are more women with diabetes than men. The urban population in developing countries is projected to double between 2000 and 2030. The most important demographic change to diabetes prevalence across the world appears to be the increase in the proportion of people greater than 65 years of age."

Diabetes can be categorized as acquired or hereditary. The lack or decrease in exercise, elevatedstress levels, and unhealthy diet all predispose an individual to Type 2 Diabetes Mellitus even without a clear family history.

Considered an endocrine disorder, this could also occur in pregnant women during a gestational stage. Susan Y. Chu, PhD, MSPH, and associates[3], in their research entitled "Maternal Obesity and Risk of Gestational Diabetes Mellitus", concluded that "high maternal weight is associated with a substantially higher risk of GDM."

In general, Diabetes Mellitus is a chronic disorder characterized by hyperglycemia or hypoglycemia (or impaired glucose tolerance), with subsequent disruption of the metabolism of carbohydrates, fats and proteins. Over time, it results in serious small and large vessel vascular complications and neuropathies.

Classic triad of Diabetes Mellitus are polydipsia (increased thirst), polyphagia (increased appetite and ingestion), and polyuria (increased urination caused by osmotic diuresis).

Amidst the increased appetite and craving for food, persons with DM (usually Type 1) may still experience weight loss because of the improper fat metabolism and breakdown of fat stores.

Other striking features include the presence of glucose and ketone bodies in the urine. Fatigue with weakness, irritability, blurred vision, numbness or tingling sensations in the hands and feet are also present.

Fasting glucose level of greater than126 mg/dl on two separate occasions is considered positive.

The strictest procedure is according to the World Health Organization, which states that the diagnosis is positive if "venous plasma glucose concentrationis greater than 11.1 mmol/L 2 hours after a 75g glucose tolerance test."

The study by Pooja Bhati et al. suggests that biomarkers of inflammation and endothelial function are correlated with Cardiac Vagal Tone and global Heart Rate Variability (HRV), which indicate some pathophysiological link between subclinical inflammation, endothelial dysfunction and cardiac autonomic dysfunction in Type 2 Diabetes Mellitus[4].

For Type 1 (insulin dependent) Diabetes, intramuscular administration of insulin is needed. Dosage is always expressed in USPunits. Humalog is the fastest acting insulin, acting within 15 minutes. The PZI has the longest peak of 8-20 hours and has the longest total duration of 36 hours. On the other hand, the Lantus is the only one "without peak" and lasts for 24 hours.

For Type 2 (non-insulin dependent) Diabetes, popular oral hypoglycemics include Metformin and Sulfonylureas. Insulin sensitizers such as Rosiglitazone and Pioglitazone are also prescribed.

Weight management, nutritional and diet counselling combined with physical therapy/exercise prescription completes the holistic treatment approach.

Therapeutic exercise programscomprise the major aspect of management. Patient education for proper foot care is an essential part of the physical therapy program for diabetic patients.

A sound, individually tailored exercise prescription is a cornerstone in the management of Diabetes Mellitus.

The goal is to address the beyond normal BMI score (25 and above) for overweight and obese patients. Numerous studies show that a regular exercise program for diabetics has a profound effect on the regulation of their blood glucose levels.

From the archives of the Journal of the American Medical Association (JAMA), a researchconducted by Daniel Umpierre, MSc and associates[5] entitled "Physical Activity Advice Only or Structured Exercise Training and Association With HbA1C Levels in Type 2 Diabetes, A Systematic Review and Meta-analysis", it was concluded that "structured exercise training that consists of aerobic exercise, resistance training, or both combined is associated with HbA1C reduction in patients with Type 2 diabetes. Structured exercise training of more than 150 minutes per week is associated with greater HbA1C declines than that of 150 minutes or less per week. Physical activity advice is associated with lower HbA1C, but only when combined with dietary advice."

Similarly, a randomized controlled trial by Timothy S. Church, MD, MPH, PhD and associates[6] which was entitled "Effects of Aerobic and Resistance Training on Hemoglobin A1C Levels in Patients With Type 2 Diabetes" made a conclusion that "among patients with Type 2 Diabetes Mellitus, a combination of aerobic and resistance training compared with the non-exercise control group improved HbA1C levels. This was not achieved by aerobic or resistance training alone."

Guidelines for a sound exercise program are as follows:

Diabetics are more prone to hypoglycemia than hyperglycemia during exercise. But physical therapists must be efficiently adept in distinguishing the differences in the signs and symptoms, including the dangerous Diabetic Ketoacidocis (DKA).

During Diabetic Ketoacidosis (DKA) the patient might experience abdominal pain, anorexia, nausea, vomiting or diarrhea. This occurs more in children. Patient will have confusion and dull mental state which can lead to coma. There is an increase in pulse rate, yet weak. There is an initial deep and rapid breathingwhich could lead to Kussmaul respiration. Cardinal sign is a fruity or acetone breath. Urine output is increased and the glucose level is extremely high (greater than 300 mg/dl). Ketones are high and pH is acidotic (less than 7.3).The skin is warm and dry.Onset is rapid, which is less than 24 hours.

While on hyperglycemia, thereare no gastrointestinal symptoms, usually occur in adults with underlying chronic disease andthe patientis also inadull, confused mental state. Skin is warm and dry, pulse and respiratory rateare high, ketone andpHlevelare normal, relatively high glucose level and the onset is slow (may take days).

On the other hand, hypoglycemia can occur with all ages. The patient may feel hungry with difficulty in concentration and coordinationwhich could eventually lead to coma. Skin is cold and clammy, there is profuse sweating, increased pulse rate, shallow respiration, considerably low glucose level,ketones and pH are normaland the onset is rapid.

Visit link:
Diabetes - Physiopedia

Posted in Diabetes | Comments Off on Diabetes – Physiopedia

Pediatric Type 1 Diabetes Mellitus: Practice Essentials …

Posted: March 12, 2020 at 3:48 am

Most pediatric patients with diabetes have type 1 diabetes mellitus (T1DM) and a lifetime dependence on exogenous insulin. Diabetes mellitus (DM) is a chronic metabolic disorder caused by an absolute or relative deficiency of insulin, an anabolic hormone. Insulin is produced by the beta cells of the islets of Langerhans located in the pancreas, and the absence, destruction, or other loss of these cells results in type 1 diabetes (insulin-dependent diabetes mellitus [IDDM]). A possible mechanism for the development of type 1 diabetes is shown in the image below. (See Etiology.)

Type 2 diabetes mellitus (noninsulin-dependent diabetes mellitus [NIDDM]) is a heterogeneous disorder. Most patients with type 2 diabetes mellitus have insulin resistance, and their beta cells lack the ability to overcome this resistance. [6] Although this form of diabetes was previously uncommon in children, in some countries, 20% or more of new patients with diabetes in childhood and adolescence have type 2 diabetes mellitus, a change associated with increased rates of obesity. Other patients may have inherited disorders of insulin release, leading to maturity onset diabetes of the young (MODY) or congenital diabetes. [7, 8, 9] This topic addresses only type 1 diabetes mellitus. (See Etiology and Epidemiology.)

Hypoglycemia is probably the most disliked and feared complication of diabetes, from the point of view of the child and the family. Children hate the symptoms of a hypoglycemic episode and the loss of personal control it may cause. (See Pathophysiology and Clinical.) [10]

Manage mild hypoglycemia by giving rapidly absorbed oral carbohydrate or glucose; for a comatose patient, administer an intramuscular injection of the hormone glucagon, which stimulates the release of liver glycogen and releases glucose into the circulation. Where appropriate, an alternative therapy is intravenous glucose (preferably no more than a 10% glucose solution). All treatments for hypoglycemia provide recovery in approximately 10 minutes. (See Treatment.)

Occasionally, a child with hypoglycemic coma may not recover within 10 minutes, despite appropriate therapy. Under no circumstances should further treatment be given, especially intravenous glucose, until the blood glucose level is checked and still found to be subnormal. Overtreatment of hypoglycemia can lead to cerebral edema and death. If coma persists, seek other causes.

Hypoglycemia was a particular concern in children younger than 4 years because the condition was thought to lead to possible intellectual impairment later in life. Persistent hyperglycemia is now believed to be more damaging.

In an otherwise healthy individual, blood glucose levels usually do not rise above 180 mg/dL (9 mmol/L). In a child with diabetes, blood sugar levels rise if insulin is insufficient for a given glucose load. The renal threshold for glucose reabsorption is exceeded when blood glucose levels exceed 180 mg/dL (10 mmol/L), causing glycosuria with the typical symptoms of polyuria and polydipsia. (See Pathophysiology, Clinical, and Treatment.)

All children with diabetes experience episodes of hyperglycemia, but persistent hyperglycemia in very young children (age < 4 y) may lead to later intellectual impairment. [11, 12]

Diabetic ketoacidosis (DKA) is much less common than hypoglycemia but is potentially far more serious, creating a life-threatening medical emergency. [13] Ketosis usually does not occur when insulin is present. In the absence of insulin, however, severe hyperglycemia, dehydration, and ketone production contribute to the development of DKA. The most serious complication of DKA is the development of cerebral edema, which increases the risk of death and long-term morbidity. Very young children at the time of first diagnosis are most likely to develop cerebral edema.

DKA usually follows increasing hyperglycemia and symptoms of osmotic diuresis. Users of insulin pumps, by virtue of absent reservoirs of subcutaneous insulin, may present with ketosis and more normal blood glucose levels. They are more likely to present with nausea, vomiting, and abdominal pain, symptoms similar to food poisoning. DKA may manifest as respiratory distress.

If children persistently inject their insulin into the same area, subcutaneous tissue swelling may develop, causing unsightly lumps and adversely affecting insulin absorption. Rotating the injection sites resolves the condition.

Fat atrophy can also occur, possibly in association with insulin antibodies. This condition is much less common but is more disfiguring.

The most common cause of acquired blindness in many developed nations, diabetic retinopathy is rare in the prepubertal child or within 5 years of onset of diabetes. The prevalence and severity of retinopathy increase with age and are greatest in patients whose diabetic control is poor. [14] Prevalence rates seem to be declining, yet an estimated 80% of people with type 1 diabetes mellitus develop retinopathy. [15]

The exact mechanism of diabetic nephropathy is unknown. Peak incidence is in postadolescents, 10-15 years after diagnosis, and it may occur in as many as 30% of people with type 1 diabetes mellitus. [16]

In a patient with nephropathy, the albumin excretion rate (AER) increases until frank proteinuria develops, and this may progress to renal failure. Blood pressure rises with increased AER, and hypertension accelerates the progression to renal failure. Having diabetic nephropathy also increases the risk of significant diabetic retinopathy.

Progression may be delayed or halted by improved diabetes control, administration of angiotensin-converting enzyme inhibitors (ACE inhibitors), and aggressive blood pressure control. Regular urine screening for microalbuminuria provides opportunities for early identification and treatment to prevent renal failure.

A child younger than 15 years with persistent proteinuria may have a nondiabetic cause and should be referred to a pediatric nephrologist for further assessment.

The peripheral and autonomic nerves are affected in type 1 diabetes mellitus. [17] Hyperglycemic effects on axons and microvascular changes in endoneural capillaries are amongst the proposed mechanisms. (In adults, peripheral neuropathy usually occurs as a distal sensory loss.)

Autonomic changes involving cardiovascular control (eg, heart rate, postural responses) have been described in as many as 40% of children with diabetes. Cardiovascular control changes become more likely with increasing duration and worsening control. [18] In a study by 253 patients with type 1 diabetes (mean age at baseline 14.4 y), Cho et al reported that the prevalence of cardiac autonomic dysfunction increases in association with higher body mass index and central adiposity. [19]

Gastroparesis is another complication, and it which may be caused by autonomic dysfunction. Gastric emptying is significantly delayed, leading to problems of bloating and unpredictable excursions of blood glucose levels.

Although this complication is not seen in pediatric patients, it is a significant cause of morbidity and premature mortality in adults with diabetes. People with type 1 diabetes mellitus have twice the risk of fatal myocardial infarction (MI) and stroke that people unaffected with diabetes do; in women, the MI risk is 4 times greater. People with type 1 diabetes mellitus also have 4 times greater risk for atherosclerosis.

The combination of peripheral vascular disease and peripheral neuropathy can cause serious foot pathology. Smoking, hypertension, hyperlipidemia, and poor diabetic control greatly increase the risk of vascular disease. Smoking, in particular, may increase the risk of myocardial infarction by a factor of 10.

Hypothyroidism affects 2-5% of children with diabetes. [20] Hyperthyroidism affects 1% of children with diabetes; the condition is usually discovered at the time of diabetes diagnosis.

Although Addison disease is uncommon, affecting less than 1% of children with diabetes, it is a life-threatening condition that is easily missed. Addison disease may reduce the insulin requirement and increase the frequency of hypoglycemia. (These effects may also be the result of unrecognized hypothyroidism.)

Celiac disease, associated with an abnormal sensitivity to gluten in wheat products, is probably a form of autoimmune disease and may occur in as many as 5% of children with type 1 diabetes mellitus. [21]

Necrobiosis lipoidica is probably another form of autoimmune disease. This condition is usually, but not exclusively, found in patients with type 1 diabetes. Necrobiosis lipoidica affects 1-2% of children and may be more common in children with poor diabetic control.

Limited joint mobility (primarily affecting the hands and feet) is believed to be associated with poor diabetic control. [22]

Originally described in approximately 30% of patients with type 1 diabetes mellitus, limited joint mobility occurs in 50% of patients older than age 10 years who have had diabetes for longer than 5 years. The condition restricts joint extension, making it difficult to press the hands flat against each other. The skin of patients with severe joint involvement has a thickened and waxy appearance.

Limited joint mobility is associated with increased risks for diabetic retinopathy and nephropathy. Improved diabetes control over the past several years appears to have reduced the frequency of these additional complications by a factor of approximately 4. Patients have also markedly fewer severe joint mobility limitations.

More:
Pediatric Type 1 Diabetes Mellitus: Practice Essentials ...

Posted in Diabetes | Comments Off on Pediatric Type 1 Diabetes Mellitus: Practice Essentials …

Diabetes – long-term effects – Better Health Channel

Posted: March 12, 2020 at 3:48 am

Diabetes is a condition in which there is too much glucose (a type of sugar) in the blood. Over time, high blood glucose levels can damage the body's organs. Possible complications include damage to large (macrovascular) and small (microvascular) blood vessels, which can lead to heart attack, stroke, and problems with the kidneys, eyes, gums, feet and nerves.Reducing risk of diabetes complicationsThe good news is that the risk of most diabetes-related complications can be reduced by keeping blood pressure, blood glucose and cholesterol levels within recommended range. Also, being a healthy weight, eating healthily, reducing alcohol intake, and not smoking will help reduce your risk.

Regular check-ups and screening are important to pick up any problems early

Enjoy a variety of foods from each food group be sure to include foods high in fibre and low in fat, and reduce your salt intake. Its helpful to consult with a dietitian to review your current eating plan and provide a guide about food choices and food quantities.

It can be daunting trying to lose weight, so to get started set yourself a short-term achievable goal. Try thinking about the food you are eating, whether you really need it, if it's a healthy choice, and consider the portion size.

If you are unable to do physical activity such as walking, swimming or gym work, then consider water aerobics, chair exercises or strength resistance training with light weights.

Check with your doctor if you are not sure whether the exercise you are planning to do is suitable or if you have a medical condition that may prevent you from doing certain types of physical activity.

Smoking is the greatest single lifestyle risk factor for developing diabetes complications. Smoking can undo all the benefits gained by weight loss, healthy eating, good blood glucose and blood pressure control.

Smoking affects circulation by increasing heart rate and blood pressure, and by making small blood vessels narrower. Smoking also makes blood cells and blood vessel walls sticky, and allows dangerous fatty material to build up. This can lead to heart attack, stroke and other blood vessel disease.

People with diabetes who smoke have higher blood glucose levels and less control over their diabetes than non-smokers with diabetes.

You can help pick up problems early by having regular checks of your:

Keeping your blood glucose levels within the recommended range can help reduce your risk of long-term diabetes-related health problems. Speak to your doctor or diabetes educator if you are unsure of your recommended blood glucose levels.

Your doctor or diabetes nurse educator may advise you to check your blood glucose levels at home depending on your individual management plan. Regular measuring of your blood glucose levels gives you information about how medication, food, exercise, illness and stress affect your diabetes.

HbA1c is a measurement of how much glucose has attached to your red blood cells over a three-month period. It is a direct measurement of your risk of long-term diabetes-related health problems.

Its recommended that you measure your HbA1c levels at least every year, but they may need to be checked every three to six months. Both HbA1c and blood glucose monitoring are important ways to assess your diabetes management.

The goal for HbA1c for most people with diabetes is no more than 53 mmol/mol or seven per cent. However, recommended ranges can vary depending on the person, for example, with children, frail elderly people, pregnant women, or the type of diabetes and its management.

Have a cholesterol and triglyceride test at least once a year. Aim for total cholesterol less than 4.0 mmol/L and triglycerides less than 2.0 mmol/L.

There are a number of causes of high cholesterol, including your family history and your diet. Too much saturated fat in your diet can increase the LDL (bad) cholesterol in your blood and result in the build-up of plaque in your blood vessels.

Foods high in saturated fats include full-fat dairy products, fatty meats, pastries, biscuits, cakes, coconut cream or coconut milk, palm oil and fatty take-away foods.

The most common long-term diabetes-related health problems are:

Other parts of the body can also be affected by diabetes, including the digestive system, the skin, sexual organs, teeth and gums, and the immune system.

Cardiovascular disease includes blood vessel disease, heart attack and stroke. It is the leading cause of death in Australia.

The risk of cardiovascular disease is greater for people with diabetes, who often have increased cholesterol and blood pressure levels. Smoking, having a family history of cardiovascular disease and being inactive also increase your risk.

To reduce your risk and pick up any problems early:

Diabetes-related eye problems include:

While most people who have damage to the eyes have no symptoms in the earlier stages, there are certain symptoms that may occur and these need urgent review. If you have flashes of light, floaters, blots and dots or part of your vision missing, see your doctor immediately.

Everyone with diabetes should have a professional eye examination by an ophthalmologist or optometrist when they are first diagnosed, and then at least every two years after that (children usually start this screening five years after diagnosis or at puberty).

It is important that you inform the person checking your eyes that you have diabetes. If retinopathy or another abnormality is found, eye tests will be required every year, or more frequently if advised by your ophthalmologist.

People with diabetes are at risk of kidney disease(nephropathy) due to changes in the small blood vessels of the kidneys. Kidney disease is painless and does not cause symptoms until it is advanced.

Screening is very important. Kidney damage can be diagnosed early by checking for microalbumin (very small amounts of protein) in the urine at least once a year. Your doctor will also check your kidney function, including estimated glomerular filtration rate (e-GFR), with a blood test.

If problems are picked up early, nephropathy can be slowed or prevented with the right treatment. Medication called ACE inhibitors and angiotensin receptor antagonists help to protect the kidneys from further damage. These tablets can also be used to treat high blood pressure.

Nerve damage (neuropathy) is usually caused by high blood glucose levels, although similar nerve damage can also result from:

Damage can occur to the sensory (feeling) and motor (movement) nerves of the legs and feet, arms, hands, chest and stomach, and to the nerves that control the actions of body organs.

To help prevent nerve damage:

Better Health Channel has more information about diabetic neuropathy.

The feet of someone with diabetes are at risk of damage when the blood supply in both large and small blood vessels is reduced. Nerve damage (peripheral neuropathy) often results and problems to the structure of the foot can also occur for example, clawed toes.

Reduced blood supply and nerve function can delay healing, increase the risk of infection, reduce feeling in the feet, and lead to ulcers and structural foot problems.

Look after your feet by:

People with diabetes may experience very dry skin due to damage to the small blood vessels and nerves. A common problem for people with diabetes is very dry skin on the feet.

There are also other skin conditions related to diabetes. High blood glucose levels over time can affect the health of the skin. The skin acts as a barrier to protect our bodies from infection so it is important to keep the skin as healthy as possible. If the skin becomes dry, it can lead to cracks and possibly infections.

To reduce the risk of skin problems:

People with poorly managed diabetes are at increased risk of tooth decay and gum infections. This is because the small blood vessels that help nourish your teeth and gums can become damaged. (Dental and gum infections can also lead to high blood glucose levels.)

Not looking after your teeth and gums can cause the gums to become inflamed and loosen around your teeth. Poor oral care is also strongly linked with an increased risk of heart disease.

To reduce your risk of teeth and gum problems:

Living with and managing either type 1 or type 2 diabetes can lead to stress, anxiety and depression. This can affect your blood glucose levels and how you manage your diabetes in general. Over time, this can affect your health.

It is important to talk to your doctor if you are going through times of stress, depression or anxiety. Your doctor can refer you to a counsellor, psychologist or psychiatrist by providing a diabetes mental health plan. This is Medicare rebated.

Other help is available, including:

You can find more information about diabetes and mental health at Diabetes Victoria.

Diabetes, particularly type 2, has been linked with Alzheimer's disease and vascular dementia. Brain changes, resulting from reduced blood supply to the brain over time, appear to be associated with an increased risk for development of these conditions.

Your immune system helps to prevent and fight infection. High blood glucose levels slow down the white blood cells, which help fight infection. This makes it more difficult for the immune system to do its job.

Support your immune system and reduce your risk of infection by:

People with either type 1 or type 2 diabetes are at increased risk of thyroid disease. This includes both overactive and underactive thyroid. Thyroid disorders can affect general health and may affect blood glucose levels.

Thyroid function is assessed by a blood test. Talk to your doctor to see if you have had your thyroid function checked.

Reduced blood supply and nerve damage can affect sexual function. Erectile dysfunction (impotence) in men is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. This is a common problem for men of all ages and is more common in men with diabetes.

Erectile dysfunction is not a disease, but a symptom of some other problem physical, psychological or a mixture of both. Most cases of erectile dysfunction are physical, such as nerve or blood vessel damage.

In women, sexual dysfunction is also reported, although there is a lack of research in this area. It is difficult to know whether this is directly related to hormonal changes such as menopause, or to diabetes.

It is important to seek help from your doctor, diabetes educator or organisations such as Andrology Australia.

Remember, you dont have to manage your diabetes on your own. There are health professionals available to help you.

Here is the original post:
Diabetes - long-term effects - Better Health Channel

Posted in Diabetes | Comments Off on Diabetes – long-term effects – Better Health Channel

Page 1,101«..1020..1,1001,1011,1021,103..1,1101,120..»